Function and Morphological Characteristics of Meibomian Gland in Patients With Renal Anemia

NCT06287879 | Unknown

• 1 other identifier: 20231121
• Study Type: interventional
• Target: 50
• Locations: 1 country
• Sites: 1

Brief Summary

Renal anemia refers to anemia in which the absolute or relative production of erythropoietin (EPO) is insufficient due to various kidney diseases, and uremic toxins affect erythropoietin production and its lifespan. Common treatment drugs for renal anemia include erythropoietin EPO and Roxadustat (FG-4592). Medical history information was collected from patients with renal anemia who visited the ophthalmology department with dry eye symptoms. This study will help to determine the function and morphological characteristics of meibomian gland in patients with renal anemia

Conditions

Dry Eye; MGD-Meibomian Gland Dysfunction

Outcome Measures

Primary Outcomes (4)

• Lacrimal river height

  Measured by dry eye analyzer machine

  Immediately and six months later

• tear break-up time

  Measured by dry eye analyzer machine

  Immediately and six months later

• tear-film lipid layer thickness

  Measured by dry eye analyzer machine

  Immediately and six months later

• meibomian glands two-dimensional digital infrared images

  Measured by dry eye analyzer

  Immediately and six months later

Study Arms (2)

Roxadustat

EXPERIMENTAL

Subjects were treated with Roxadustat for renal anemia

Diagnostic Test: Dry eye examination

EPO

ACTIVE COMPARATOR

Subjects were treated with EPO for renal anemia

Diagnostic Test: Dry eye examination

Interventions

Dry eye examination DIAGNOSTIC_TEST

1. Lacrimal river height 2. tear break-up time 3. tear-film lipid layer thickness 4. meibomian glands two-dimensional digital infrared images

EPO; Roxadustat

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• long-term use of Roxadustat or erythropoietin for renal anemia

You may not qualify if:

• contact lens wearer, history of eye surgeries, systemic health conditions affecting ocular health and those who were unable to cooperate with examinations

Sponsors & Collaborators

• Zhongnan Hospital: lead

Study Sites (1)

Zhongnan Hospital of Wuhan University

Wuhan, Hubei, 430071, China

RECRUITING

MeSH Terms

Conditions

Dry Eye Syndromes; Meibomian Gland Dysfunction

Condition Hierarchy (Ancestors)

Lacrimal Apparatus Diseases; Eye Diseases; Eyelid Diseases

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: OTHER
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 1, 2024
• First Posted: March 1, 2024
• Study Start: April 1, 2023
• Primary Completion: December 20, 2024
• Study Completion: December 30, 2024
• Last Updated: March 1, 2024

Record last verified: 2023-11

Locations

CN (1)